Comparative Pharmacology
Head-to-head clinical analysis: DURICEF versus KEFTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURICEF versus KEFTAB.
DURICEF vs KEFTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
500 mg to 1 g orally once or twice daily.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
None Documented
None Documented
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic